Pagina 20 van 25

Re: Innate Pharma

Geplaatst: 15 Mei 2019 09:32
door besportie
May 15 (Reuters) - INNATE PHARMA SA IPH.PA :
* INNATE PHARMA FIRST QUARTER 2019 REPORT
* Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY
AMOUNTED TO EUR 237.1 MILLION
* IPH5401 DOSE-ESCALATION STUDY IS ON TRACK; SAFETY UPDATE
AND
COHORT EXPANSION EXPECTED IN 2H2019
* COMMITTED TO EXECUTE ON OUR CLINICAL PLANS AND WILL
PROVIDE DATA
UPDATES ON MANY OF OUR PROGRAMS THROUGHOUT REST OF YEAR AND INTO
2020

Source text for Eikon:

Re: Innate Pharma

Geplaatst: 15 Mei 2019 11:11
door bertje
3.7 euro cash per aandeel, veel waarde plakt men ook nog niet op de pipeline.

Re: Innate Pharma

Geplaatst: 16 Mei 2019 10:06
door Brammeke
Pakketje 09/05/2019 aan 5,70 verkocht aan 6,08.
gem: 5,365.

Re: Innate Pharma

Geplaatst: 16 Mei 2019 10:09
door Marbull
Ik blijf zitten, onder de 6.5 gaat er niets weg !! 8-)

Re: Innate Pharma

Geplaatst: 16 Mei 2019 11:21
door bertje
Vermoed ook het begin van de stijging, cash en vooruitgang in onderzoeken lijken positief.

Re: Innate Pharma

Geplaatst: 21 Mei 2019 15:01
door Bioscience
bertje schreef:Vermoed ook het begin van de stijging, cash en vooruitgang in onderzoeken lijken positief.


Heel vreemd verloop van de koers de laatste week . Lijkt inderdaad dat er een soort uitschut situatie is gecreëerd om wat mensen te laten uitstappen . Is ook bij Ablynx en Argenx gebeurd net voor de grote stijging begon .

Goed vasthouden deze aandeeltjes . Verwacht nog wel een grote koerssprong als we zien wat nu de lage waardering is voor de
hele pipeline excl. cash . Als Astrazeneca / Novo Nordisk ( die naast het net viste bij Ablynx ) / Bristol M /Sanofi de boel maar niet goedkoop opslokt op deze koers . Meer dan 225 miljoen cash ! Nemen ze de hele pipeline over voor 160 miljoen .

( Industrial collaborations
Innate Pharma has a multi-term agreement with AstraZeneca. Innate Pharma has had a partnership for 10 years with Novo Nordisk A/S. Lirilumab is developed by our partners Bristol-Myers Squibb (license agreement). Innate Pharma is also collaborating with Sanofi (research collaboration and licensing agreement) for the development of innovative bispecific antibody formats.

Clinical collaborations
The Company is also collaborating with a large number of world leading cancer centres and clinical networks such as, in France, the cooperative groups ALFA et GOELAMS, the Institut Gustave Roussy and the Hôpital Saint Louis in Paris, the Institut Paoli-Calmettes in Marseille; and in the United States, the Ohio State’s James Cancer Hospital, the Dana-Farber Cancer Institute, the Memorial Sloan-Kettering Cancer Center, and the National Cancer Institutes (NCI). )

Re: Innate Pharma

Geplaatst: 22 Mei 2019 20:08
door Stofke
Thorbald van Hall highlights monalizumab from @InnatePharma in plenary presentation at #CIMT2019 on “NKG2A as a novel checkpoint on CD8 T cells.”

Re: Innate Pharma

Geplaatst: 23 Mei 2019 07:12
door Stofke
INNATE PHARMA ANNONCE UNE PUBLICATION DANS “CELL REPORTS”SUR UNE NOUVELLE GÉNÉRATION D'IMMUNOTHÉRAPIES CIBLANT LA VOIE ADÉNOSINE

https://www.innate-pharma.com/sites/def ... s_5253.pdf

Re: Innate Pharma

Geplaatst: 23 Mei 2019 10:56
door Brammeke
"Los" pakketje gekocht aan 5,68.
gem: 5,389.

Re: Innate Pharma

Geplaatst: 23 Mei 2019 14:44
door Bioscience
Goede aankoop Brammeke

https://www.innate-pharma.com/en/news-e ... ll-reports

INNATE PHARMA ANNOUNCES PUBLICATION ON NEXT GENERATION IMMUNOTHERAPIES TARGETING THE ADENOSINE PATHWAY IN “CELL REPORTS”
Thursday, May 23, 2019 - 07:00

The production of adenosine via CD39 and CD73 enzymes participates in an immunosuppressive tumor microenvironment.
Perrot et al. generated two antibodies, IPH5201 and IPH5301, targeting human CD39 and CD73, respectively.
In vitro and in vivo data support the use of anti-CD39 and anti-CD73 mAbs in combination cancer therapies.


Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced a publication in Cell Reports describing two new monoclonal antibodies, IPH5201 and IPH5301, that target CD39 and CD73, respectively, to inhibit the adenosine pathway and promote activation of the immune system against cancer. The full manuscript, titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies” appeared in the online issue of Cell Reports on May 21st, 2019.

Cancer immune evasion largely involves the generation of high amounts of immunosuppressive adenosine (Ado) within the tumor environment. An increase in CD39 and CD73 at the tumor bed signals an immunosuppressive environment inhibiting anti-tumor immune responses and favoring tumor spreading. The impact of blocking CD39 and CD73 ectoenzymes to overcome Ado-mediated immunosuppression and to reinforce anti-tumor immunity has been investigated by combining genetic and antibody-mediated approaches.

The work published by Innate Pharma and collaborators shows that CD39 deficiency enhances the benefits from combined cancer therapies in preclinical mouse solid tumor models. We report the generation and characterization of two blocking antibodies against human CD39 and CD73, referred to as IPH5201 and IPH5301, respectively. The anti-CD39 antibody IPH5201 blocked ATP hydrolysis by both membrane and soluble CD39, thereby promoting DC maturation and macrophage activation, whereas the anti-CD73 antibody IPH5301 blocked the degradation of AMP into immunosuppressive Ado and displays different functional characteristics over currently used antibodies. Both IPH5201 and IPH5301 prevented the Ado-mediated inhibition of T cells purified from patients with breast cancer or melanoma. We also observed that IPH5201 efficiently increased the anti-tumor activity of the ATP-inducing chemotherapeutic drug oxaliplatin in a mouse tumor model. These data provide the scientific rationale for the clinical development of IPH5201 and IPH5301 and their use in cancer immunotherapy.

“The published data continue to support our rationale to evaluate IPH5201 and IPH5301 in cancer, particularly if these antibodies are used in combination with each other, with immune checkpoint inhibitors or with chemotherapies”, commented Pr. Eric Vivier, Innate Pharma CSO. “We are excited to further explore the potential of these antibodies as an innovative and differentiated approach to reverse immunosuppression in the tumor microenvironment and expect INDs to be filed for IPH5201 in the second half of 2019 and for IPH5301 in the first half of 2020.”

In October 2018, Innate Pharma and AstraZeneca entered into a development collaboration and option agreement for further co-development and co-commercialization for IPH5201.



Reference

Ivan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, Séverine Augier, Aurélie Docquier, Laurent Gros, Rachel Courtois, Cécile Déjou, Diana Jecko, Ondine Becquart, Hélène Rispaud-Blanc, Laurent Gauthier, Benjamin Rossi, Stéphanie Chanteux, Nicolas Gourdin, Beatrice Amigues, Alain Roussel, Armand Bensussan, Jean-François Eliaou, Jérémy Bastid, François Romagné, Yannis Morel, Emilie Narni-Mancinelli, Eric Vivier, Carine Paturel, and Nathalie Bonnefoy. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Reports, May 21, 2019.